NCT01612221View on ClinicalTrials.gov

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Patients at Risk for Melanoma
Interventions
DRUG

N-acetylcysteine

N-acetylcysteine (NAC), 1200 mg Oral route 2 doses

OTHER

Placebo arm

Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT01612221 - Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo | Biotech Hunter | Biotech Hunter